CRINETICS PHARMACEUTICALS IN (CRNX)

US22663K1079 - Common Stock

53.91  +1.17 (+2.22%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRNX. CRNX was compared to 568 industry peers in the Biotechnology industry. While CRNX has a great health rating, there are worries on its profitability. CRNX is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CRNX has reported negative net income.
In the past year CRNX has reported a negative cash flow from operations.
CRNX had negative earnings in each of the past 5 years.
In the past 5 years CRNX always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of CRNX (-29.65%) is better than 68.50% of its industry peers.
CRNX's Return On Equity of -33.36% is fine compared to the rest of the industry. CRNX outperforms 77.35% of its industry peers.
Industry RankSector Rank
ROA -29.65%
ROE -33.36%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRNX has more shares outstanding
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

CRNX has an Altman-Z score of 26.79. This indicates that CRNX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 26.79, CRNX belongs to the top of the industry, outperforming 94.87% of the companies in the same industry.
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 26.79
ROIC/WACCN/A
WACC11.83%

2.3 Liquidity

A Current Ratio of 16.38 indicates that CRNX has no problem at all paying its short term obligations.
CRNX's Current ratio of 16.38 is amongst the best of the industry. CRNX outperforms 90.80% of its industry peers.
A Quick Ratio of 16.38 indicates that CRNX has no problem at all paying its short term obligations.
CRNX has a Quick ratio of 16.38. This is amongst the best in the industry. CRNX outperforms 90.80% of its industry peers.
Industry RankSector Rank
Current Ratio 16.38
Quick Ratio 16.38

More info and screens

5

3. Growth

3.1 Past

CRNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.47%.
The Revenue for CRNX has decreased by -78.03% in the past year. This is quite bad
CRNX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.55% yearly.
EPS 1Y (TTM)-2.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
Revenue 1Y (TTM)-78.03%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Sales Q2Q%-100%

3.2 Future

CRNX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.22% yearly.
Based on estimates for the next years, CRNX will show a very strong growth in Revenue. The Revenue will grow by 160.91% on average per year.
EPS Next Y-2.1%
EPS Next 2Y-3.54%
EPS Next 3Y-8.12%
EPS Next 5Y13.22%
Revenue Next Year-60.77%
Revenue Next 2Y0.8%
Revenue Next 3Y103.81%
Revenue Next 5Y160.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CRNX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CRNX's earnings are expected to decrease with -8.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.54%
EPS Next 3Y-8.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (12/20/2024, 12:06:57 PM)

53.91

+1.17 (+2.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners91.19%
Inst Owner Change2.48%
Ins Owners1.02%
Ins Owner Change-1.94%
Market Cap5.00B
Analysts84
Price Target76.26 (41.46%)
Short Float %6.73%
Short Ratio7.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.32%
Min EPS beat(2)-7.29%
Max EPS beat(2)-3.35%
EPS beat(4)0
Avg EPS beat(4)-6.4%
Min EPS beat(4)-12.64%
Max EPS beat(4)-2.31%
EPS beat(8)0
Avg EPS beat(8)-6.4%
EPS beat(12)1
Avg EPS beat(12)-7.31%
EPS beat(16)2
Avg EPS beat(16)-7.17%
Revenue beat(2)0
Avg Revenue beat(2)-61.65%
Min Revenue beat(2)-100%
Max Revenue beat(2)-23.3%
Revenue beat(4)1
Avg Revenue beat(4)-19.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)145.52%
Revenue beat(8)5
Avg Revenue beat(8)126.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.85%
PT rev (3m)6.23%
EPS NQ rev (1m)-0.34%
EPS NQ rev (3m)-0.34%
EPS NY rev (1m)-0.24%
EPS NY rev (3m)-0.15%
Revenue NQ rev (1m)2.27%
Revenue NQ rev (3m)2.27%
Revenue NY rev (1m)-15.54%
Revenue NY rev (3m)-13.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4811.95
P/FCF N/A
P/OCF N/A
P/B 6
P/tB 6
EV/EBITDA N/A
EPS(TTM)-3.73
EYN/A
EPS(NY)-3.97
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS0.01
BVpS8.98
TBVpS8.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.65%
ROE -33.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.43%
Cap/Sales 361.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.38
Quick Ratio 16.38
Altman-Z 26.79
F-Score4
WACC11.83%
ROIC/WACCN/A
Cap/Depr(3y)214.72%
Cap/Depr(5y)143.85%
Cap/Sales(3y)64.19%
Cap/Sales(5y)101.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
EPS Next Y-2.1%
EPS Next 2Y-3.54%
EPS Next 3Y-8.12%
EPS Next 5Y13.22%
Revenue 1Y (TTM)-78.03%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Sales Q2Q%-100%
Revenue Next Year-60.77%
Revenue Next 2Y0.8%
Revenue Next 3Y103.81%
Revenue Next 5Y160.91%
EBIT growth 1Y-47.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.64%
EBIT Next 3Y-24.04%
EBIT Next 5YN/A
FCF growth 1Y-95.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.18%
OCF growth 3YN/A
OCF growth 5YN/A